Elimination of Nadolol by Patients with Renal Impairment
Overview
Authors
Affiliations
1 Nadolol excretion was studied in 24 patients with chronic renal failure. 2 The amount of nadolol excreted during the 120-h period after receiving the drug ranged from less than 1% in functionally anephric, patients up to 11.5% in patients with average creatinine clearance of 57.9 +/- 3.6 ml/min/1.73 m2. 3 Renal clearance of nadolol was found to correlate with creatinine clearance; nadolol elimination is retarded in patients with renal failure. 4 Nadolol serum half-life is prolonged in proportion to the remaining renal function. Therefore, dosage intervals in renal patients receiving nadolol should be adjusted to creatinine clearance. 5 Haemodialysis effectively reduced serum concentration of the drug; it may therefore be a useful therapy for drug intoxication.
Kalsoom S, Rasool M, Imran I, Saeed H, Ahmad T, Alqahtani F Pharmaceuticals (Basel). 2024; 17(2).
PMID: 38399480 PMC: 10891759. DOI: 10.3390/ph17020265.
Bouchard J, Shepherd G, Hoffman R, Gosselin S, Roberts D, Li Y Crit Care. 2021; 25(1):201.
PMID: 34112223 PMC: 8194226. DOI: 10.1186/s13054-021-03585-7.
Cardiovascular drug therapy in the elderly: theoretical and practical considerations.
Williams B, Kim J Drugs Aging. 2003; 20(6):445-63.
PMID: 12710864 DOI: 10.2165/00002512-200320060-00004.
Bioequivalence of a highly variable drug: an experience with nadolol.
Buice R, Subramanian V, Duchin K Pharm Res. 1996; 13(7):1109-15.
PMID: 8842054 DOI: 10.1023/a:1016031313065.
The new beta-adrenergic antagonists.
Chung D, Laschuk M Can Anaesth Soc J. 1984; 31(4):430-3.
PMID: 6146393 DOI: 10.1007/BF03015419.